Nichols Asset Management Lowers stake in Cambrex Corporation (CBM)

Cambrex Corporation (CBM) : Nichols Asset Management reduced its stake in Cambrex Corporation by 0.81% during the most recent quarter end. The investment management company now holds a total of 180,450 shares of Cambrex Corporation which is valued at $8,210,475 after selling 1,478 shares in Cambrex Corporation , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Cambrex Corporation makes up approximately 1.77% of Nichols Asset Management’s portfolio.

Cambrex Corporation closed down -0.28 points or -0.62% at $44.82 with 2,75,709 shares getting traded on Wednesday. Post opening the session at $44.91, the shares hit an intraday low of $44.08 and an intraday high of $45.12 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Strs Ohio sold out all of its stake in CBM during the most recent quarter. The investment firm sold 20,800 shares of CBM which is valued $946,400.New York State Teachers Retirement System boosted its stake in CBM in the latest quarter, The investment management firm added 2,800 additional shares and now holds a total of 112,515 shares of Cambrex Corporation which is valued at $5,119,433. Cambrex Corporation makes up approx 0.01% of New York State Teachers Retirement System’s portfolio. Simplex Trading sold out all of its stake in CBM during the most recent quarter. The investment firm sold 1,615 shares of CBM which is valued $69,736.Creative Planning reduced its stake in CBM by selling 4,000 shares or 90.91% in the most recent quarter. The Hedge Fund company now holds 400 shares of CBM which is valued at $17,084.

On the company’s financial health, Cambrex Corporation reported $1.01 EPS for the quarter, beating the analyst consensus estimate by $ 0.16 according to the earnings call on Feb 9, 2016. Analyst had a consensus of $0.85. The company had revenue of $156.19 million for the quarter, compared to analysts expectations of $156.94 million. The company’s revenue was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 EPS.

Many Wall Street Analysts have commented on Cambrex Corporation. Shares were Reiterated by Singular Research on Feb 11, 2016 to “Buy” and Lowered the Price Target to $ 60 from a previous price target of $63 .Cambrex Corporation was Initiated by Sidoti to “Buy” on Feb 1, 2016.

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs) pharmaceutical intermediates and to a lesser extent other fine chemicals. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.

Leave a Reply

Cambrex Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cambrex Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.